|View printer-friendly version|
- BioTime Plans Distribution of Shares of
Subsidiary OncoCyte Corporationto BioTime Shareholders
- Planned Distribution to Allow OncoCyte Greater Access to Capital Markets as a
Publicly Traded Company
The filing represents an important milestone in separating BioTime’s therapeutics and cancer diagnostics businesses.
OncoCyte is engaged in the development of new “liquid biopsy” diagnostic tests for cancer based on analyzing patient blood or urine samples for specific gene or protein markers indicative of the presence of particular types of cancer. OncoCyte is presently developing diagnostic tests for lung cancer, breast cancer and bladder cancer.
More information about OncoCyte and the planned shared distribution can be found in the Information Statement filed as an exhibit to OncoCyte’s Form 10 Registration Statement, which is available on the “Latest News” page of OncoCyte’s website: www.oncocyte.com and the website maintained by the
This press release does not constitute an offer to sell or a solicitation of an offer to buy any OncoCyte securities. The distribution of OncoCyte common stock by
BioTime’s subsidiaries include the publicly traded
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing
Dan L. Lawrence, 510-775-0510
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Gotham Communications, LLC
Bill Douglass, 646-504-0890
Gelbart-Kahana Investor Relations
Zeev Gelbart, +972-3-6074717